Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform


Out of Business LATEST DEAL TYPE

Developer of vaccines that are designed to selectively and specifically generate effective antibody-inducing immune responses. The company's vaccines are based on its proprietary peptide chemistry technology, providing users with vaccines that are safer, more stable and less expensive than current vaccines.

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Primary Office
  • 708 Quince Orchard Road
  • Gaithersburg, MD 20878
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Ariavax’s full profile, request a free trial.

Ariavax Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jun-2013 Completed Out of Business
3. Grant 01-Feb-2009 00000 Completed Generating Revenue
2. Grant 01-May-2005 $218K Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »